Iterum Therapeutics plc
ITRM
$0.6833
-$0.0377-5.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.04% | 36.59% | 35.44% | 1.75% | 49.70% |
| Total Depreciation and Amortization | 8.75% | -52.61% | -83.77% | -73.53% | -49.40% |
| Total Amortization of Deferred Charges | -41.94% | -17.90% | -2.18% | 82.50% | -1.20% |
| Total Other Non-Cash Items | 197.10% | 198.85% | 204.51% | 136.43% | -137.58% |
| Change in Net Operating Assets | 74.60% | -130.29% | -560.77% | -283.59% | -556.06% |
| Cash from Operations | 64.87% | 60.89% | 31.93% | -14.97% | -61.18% |
| Capital Expenditure | -300.00% | 69.23% | 84.62% | 96.55% | 101.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -73.11% | -56.79% | -22.01% | 114.98% | -14.98% |
| Cash from Investing | -73.12% | -56.78% | -21.97% | 115.85% | -14.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 285.62% | 222.24% | 2,481.33% | 1,426.54% | 819.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.91% | 38.30% | 2,481.33% | 1,426.54% | 819.70% |
| Foreign Exchange rate Adjustments | 41.46% | 6.58% | -22.95% | -335.00% | -228.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 191.92% | 155.74% | 220.19% | 154.70% | -294.84% |